Tag: cetuximab

1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor (binimetinib) led to longer overall disease survival in patients with BRAF V600E mutated metastatic colorectal cancer as compared to control groups who received a single...
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) and a MEK inhibitor (binimetinib) led to longer overall disease survival in patients with BRAF V600E mutated metastatic colorectal cancer as compared to control groups who received a single...
Image: PD 1. The addition of cetuximab to chemotherapy before and after surgery decreases survival in colorectal cancer with resectable liver metastases. 2. The negative effect of cetuximab was most significant in tumors with normally more favorable prognostic factors. Evidence rating: 1 (Excellent) Study Rundown:  The EGFR inhibitor, cetuximab, has been previously shown...